System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Jin-Yuan Shih

Oncology — National Taiwan University Hospital, Taiwan

LeadR Profile

Jin-Yuan Shih National Taiwan University Hospital Taiwan
1 286 ScienceLeadR Reputation 1286

Unlock

Register Login
Network Map

Oncology

Subspecialties: Pulmonology - Public Health

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Organizations

Source: Pubmed

National Taiwan University Hospital

Publications Synthesis

Source: Pubmed

Number : 365

Citations

Citations: 20 952 1st author: 21 Last author: 91 Unique author: 1

Main journals

J Thorac Oncol 38
Lung Cancer 23
J Clin Oncol 20
J Formos Med Assoc 19
Cancer Res 14

Best Journals

J Clin Oncol 9
Ann Oncol 6
N Engl J Med 4

Breakdown by type

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Mechanisms of Acquired Resistance Following Dual EGFR/MET Inhibition in MET-Amplified EGFR TKI-Resistant Lung Cancer.
cells, lung, neoplasms, lung neoplasms, cell line, therapeutics		Mol Cancer Ther20260
Utility of various programmed death-ligand 1 (PD-L1) assays in predicting the clinical benefit of immune checkpoint inhibitors in PD-L1-expressing non-small-cell lung cancer patients: a systematic review.
cells, b7-h1 antigen, lung, neoplasms, carcinoma, non-small-cell lung, immune checkpoint inhibitors, lung neoplasms, small cell lung carcinoma, nivolumab, therapeutics, ligands		Transl Lung Cancer Res20260
A deep learning model based on ultrasound imaging to differentiate malignant from benign pleural effusion: a multicenter cohort study.
pleural effusion, ultrasonography, cohort studies, deep learning, learning		Respir Res20260
Real-World Outcomes of Sequential Afatinib and Osimertinib Versus Afatinib and Chemotherapy in EGFR-Mutant NSCLC: Taiwan Multicenter GIANT Study.
neoplasms, carcinoma, non-small-cell lung, drug therapy, afatinib, therapeutics, mutation, chemotherapy		Target Oncol20260
EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.
cells, lung, neoplasms, carcinoma, non-small-cell lung, drug therapy, lung neoplasms, small cell lung carcinoma, therapeutics, mutation, chemotherapy, egfr mutation		Lung Cancer20260

Clinical Studies 11

Source: ClinicalTrials

Synthesis

Study Chair: 1

By phase:

Phase 3 5
N/A 4
Phase 2 1
Phase 2/Phase 3 1

By status:

Active not recruiting 6
Completed 3
Recruiting 1
Unknown 1

By type:

Interventional 7
Observational 4

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 1
multicentric5to9 0
multicentricup10 8

Main Topics

Respiratory Tract Diseases 11

Ongoing Clinical Trials

2 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Pan Asian Clinical Database of EGFR Exon 20 Insertion Mutated NSCLC
NCT06418412 — cells, epidemiology, lung, neoplasms, carcinoma, non-small-cell lung, exons, lung neoplasms, small cell lung carcinoma, carcinoma		N/ARecruiting2024
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
NCT05740566 — cells, lung, neoplasms, drug therapy, lung neoplasms, small cell lung carcinoma, topotecan, chemotherapy, carcinoma		Phase 3Active not recruiting2023

LeadR Networks

Main global connection map

Source: Pubmed Source: ClinicalTrials